Flomics just launched a crowdfunding campaign with Capital Cell, to support its validation studies on the early detection of different types of cancer. Capital Cell is the leading health-focused crowd equity platform, allowing this rare opportunity to the general public to help the project and become Flomics shareholder. Join us in the fight against cancer!
🔬 Flomics groundbreaking technology uses RNA biomarkers, Next Generation Sequencing and AI algorithms to arrive at an accurate early detection of multiple types of cancer, from a standard blood sample.
Why invest in Flomics?
Join a startup making significant strides in early detection of cancer.
Promising results in the early detection of 5 types of cancer.
Support a revolutionary solution with the potential to save lives.
Invest in a cancer-free future! Become a shareholder of Flomics today! Tickets starting at €500
For more details:
Flomics crowdfunding campaign with Capital Cell
